Please Subscribe to get a daily link to Pat's blog via email

Subscribe!

Your privacy is important to us. We will never spam you and keep your personal data secure.

daratumumab

Home/Tag:daratumumab
26 12, 2015

Video highlights of my first few days at ASH

Tags: , , |4 Comments

Good friend and fellow myeloma survivor, Jenny Ahlstrom, is a lot better at the technical side of blogging than I am. She uses a lot of video on her site. Jenny interviewed me on Sunday at ASH. You can listen to it here: http://www.myelomacrowd.org/live-from-ash/ Now that we're past the holiday, I'm going to be going

23 12, 2015

Canadian patients need help getting daratumumab

Tags: , , |0 Comments

My good friend from north of the border, Nancy Shamanna, asked me to share this link to a survey for patients that have taken daratumumab (Darzalex). She's hoping a positive response might move Canadian officials to adopt the new immunotherapy sooner rather than later: Myeloma Canada seeks patient and caregiver treatment input Dear patient/caregiver, Myeloma

8 12, 2015

More drugs are good, but aren’t enough

Tags: , , , , , |9 Comments

Data for more than a dozen "new" myeloma drugs was presented at this week's American Society of Hematology (ASH) meetings here in Orlando. As I described yesterday, several are hopeful crossover drugs; compounds that are already FDA approved for use against other cancers. Keytruda, known chemically as pembrolizumab, and ricolinostat (ACY-1215), another possible cross over

7 12, 2015

BREAKING NEWS: Early data featuring Darzalex in combination with Revlimid

Tags: , , , |6 Comments

As promised, here are details from a preliminary study showing impressive response rates when Darzalex (daratumumab) is combined with Revlimid and dexamethasone. Similarly impressive numbers were also achieved when the immunotherapy drug was used along with pomalidomide. I'll pass along those details later today after that data is presented. Back to Darzalex and Revlimid. Very

1 12, 2015

More about elotuzumab (Empliciti). Are immunotherapies the answer?

Tags: , , , , , |0 Comments

In my haste to get the news out about elotuzumab's FDA approval yesterday, I mistakenly relied on a Cure Magazine article that stated Kyprolis was the drug used in combination with elo. I was surprised, but ran with it. I should have known better. The Cure Magazine article was mistaken. Elotuzumab (Empliciti), Revlimid and dexamethasone

25 11, 2015

Financial aid: Takeda wants to help. Lets work together

Tags: , , , , , , , |6 Comments

I had an opportunity to interview several Takeda Pharmaceutical team members about the company's new oral, proteasome inhibitor, Ninlaro (ixazomib), yesterday afternoon. I have heard from dozens of patients who find themselves stuck paying thousands of dollars out-of-pocket for two established oral chemotherapy drugs, Revlimid and Pomalyst. I'm concerned that the same obstacles might face

16 11, 2015

BREAKING NEWS: FDA approves daratumumab

Tags: , , |0 Comments

I expected daratumumab to garner FDA approval sometime after ASH. So when I saw a news alert earlier today announcing that Darzalex had been approved, I didn't pay any attention. But it didn't take long for me to figure out that Darzalex is the new trade name for daratumumab. By any name, this is wonderful

14 10, 2015

Reader celebrating great response to daratumumab

Tags: , |10 Comments

I'm often said our readers are my best resource. Early reports about the new immunotherapy, daratumumab, have been good. Mike, from North Carolina, recently enrolled in a dara trial. He emailed me about how great it's working for him and agreed to share an email he sent his friends, trumpeting the early results. Here's a

2 09, 2015

Two promising new myeloma therapies: ABT-199 and daratumumab

Tags: , |4 Comments

I just heard from a patient's daughter. Her mother is joining a clinical trial for ABT-199 at Mayo Clinic in Minnesota. Apparently the myeloma team there is openly enthusiastic about the drug's potential. ABT-199 is a Bcl-2 inhibitor, targeting the BCL-2 protein. The experimental drug has produced remarkable success against several other types of blood

27 08, 2015

BREAKING NEWS: Daratumumab pushes forward toward FDA approval

Tags: , , , , |1 Comment

Important news as the promising new immunotherapy, daratumumab, continues to move swiftly toward FDA approval. My friends at Genmab and Jannsen in the Netherlands emailed me details last evening, along with some helpful background information to review: Daratumumab is an investigational human anti-CD38 monoclonal antibody that received Breakthrough Therapy Designation from the FDA in May,

14 08, 2015

Understanding our future: immunotherapies

Tags: , , |2 Comments

I just listened to one of the best and easiest to understand videos I've found, explaining how the new monoclonal antibodies (elotuzumab and daratumumab) work. My good friend and long lived myeloma survivor, Jack Aiello, is interviewing Dana-Farber's Dr. Paul Richardson on a Patient Power broadcast. It's short and to the point. Give it a